Cao L.-H.,Hepatic Disease Center |
Liu Z.-M.,Hepatic Disease Center |
Zhao P.-L.,Hepatic Disease Center |
Sun S.-C.,Maternal and Child Hospital of Qinhuangdao City |
And 3 more authors.
Genetics and Molecular Research | Year: 2015
The aim of this study was to examine the efficacy of combined immunization of hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine (HBVac) in blocking father-infant transmission of hepatitis B virus (HBV). Newborns positive at birth for blood HBV surface antigen (HBsAg) and/or HBV DNA were selected and immunized with HBIG combination HBVac. At 7 months, HBV markers and HBV DNA of each neonate were measured using electrochemiluminescence with the Cobas-e-411 Automatic Electrochemiluminescence Immunoassay Analyzer and fluorescence quantitative polymerase chain reaction. Among all 7-month-old subjects, the negative conversion rates of HBV DNA and HBsAg were 48/61 (78.7%) and 19/41 (46.3%), respectively. Therefore, this study demonstrated that prompt combination injection of HBIG and HBVac can protect some of the HBV DNA- and/or HBsAg-positive newborns from HBV. © FUNPEC-RP. Source